IP Library Granted Patent US 9,192,601
Granted Patent B2
US 9,192,601 · App. 12/810,123 · Granted Nov 24, 2015

Methods for enhancing muscle performance and tone

Inventors: Ronald M. Evans (La Jolla, CA); Vihang A. Narkar (San Diego, CA); Reuben J. Shaw (San Diego, CA); Michael Downes (San Diego, CA); Ruth T. Yu (La Jolla, CA)
Assignee: Salk Institute for Biological Studies
A61K31/426A61K31/4178A61K31/47C12Q1/6876
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,192,601
App. No.
12/810,123
Granted
Nov 24, 2015
Kind
B2
Abstract

Provided herein are methods and compositions for improving muscle performance and increasing endurance. Agonists of AMP-activated protein kinase (AMPK) and agonists of peroxisome proliferator-activated receptor delta (PPARδ) can be used in such treatments.

Claims (14)

1. A method for improving muscle endurance in a subject independent of exercise, the method comprising administering to the subject an effective amount of an AMP kinase (AMPK) agonist, wherein the AMPK agonist is 5-amino-4-imidazolecarboxamide riboside (AICAR), and an effective amount of a PPARδ agonist, wherein the PPARδ agonist is (2-methyl-4(((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)methyl)sulfonyl)phenoxy) acetic acid (GW1516), thereby improving muscle endurance in a subject independent of exercise.

2. The use method of claim 1 , wherein the subject has a muscle wasting disease or disorder.

3. The method of claim 1 , wherein the subject is a racing mammal.

4. The method of claim 3 , wherein the racing mammal is a horse, a dog, or a human.

5. The method of claim 1 , wherein the subject is an adult.

6. The method of claim 1 , wherein the subject is an exercise-trained subject.

7. The method of claim 1 , wherein the PPARδ agonist is administered on the same day(s) on which the AMPK agonist is administered.

8. The method of claim 1 , further comprising having the subject perform aerobic exercise.

9. The method of claim 1 , wherein improved endurance comprises improved running distance or improved running time or a combination thereof

10. The method of claim 1 , wherein fatty acid oxidation is increased in at least one skeletal muscle of the subject.

11. The method of claim 1 , wherein body fat is reduced.

12. The method of claim 11 , wherein the body fat is white adipose tissue.

13. The method of claim 1 , wherein the individual has a neuromuscular disease.

14. The method of claim 1 , wherein the individual does not participate in substantial exercise prior to experiencing improved muscular endurance following the administering step.

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 23, 2013
From: SALK INSTITUTE FOR BIOLOGICAL STUDIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031289/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2010
From: DOWNES, MICHAEL; YU, RUTH T.
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 025533/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2010
From: EVANS, RONALD M.; NARKAR, VIHANG A.; SHAW, REUBEN J.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 025533/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2010
From: HOWARD HUGHES MEDICAL INSTITUTE
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 025533/0637 →
Continuity (4)
Continuation In Part 11966851 · Dec 28, 2007
Continuation In Part PCTUS2007089124 · Dec 28, 2007
Provisional Application 60882774 · Dec 29, 2006
Related Publication 20110112047A1 · May 12, 2011